VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
June 24th 2022Change in HbA1c as a guide for T2D treatment intensification is steadily yielding to presence of/risk for comorbidities as pluripotent agents win guideline favor, observes a VA clinical investigator.